Northwestern Sells Drug Royalty Rights For $700M
Researchers at Northwestern first synthesized the chemical compound pregabalin, which is the basis for the drug. The payment will largely end up in Northwestern University's endowment, with a portion reserved for those researchers.
“Essentially, we are converting a potential stream of future royalty revenues from Lyrica into an immediate cash payment,” said Eugene S. Sunshine, Northwestern's...
To view the full article, register now.